Ray Dalio Repligen Corp Transaction History

Bridgewater Associates, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$162.42 - $220.56 $759,151 - $1.03 Million	4,674 Added 210.16%	6,898 $1.17 Million
Q3 2022 Nov 10, 2022	SELL	$160.42 - $256.21 $222,342 - $355,107	-1,386 Reduced 38.39%	2,224 $416,000
Q2 2022 Aug 11, 2022	BUY	$140.68 - $188.02 $86,940 - $116,196	618 Added 20.66%	3,610 $586,000
Q1 2022 May 13, 2022	BUY	$161.19 - $257.96 $482,280 - $771,816	2,992 New	2,992 $563,000
Q4 2021 Feb 14, 2022	SELL	$247.59 - $304.47 $182,226 - $224,089	-736 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$194.77 - $324.21 $143,350 - $238,618	736 New	736 $213,000

487

54.4M

341K

235K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $6.92B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.